tiprankstipranks
Trending News
More News >
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
US Market
Advertisement

Day One Biopharmaceuticals (DAWN) AI Stock Analysis

Compare
349 Followers

Top Page

DAWN

Day One Biopharmaceuticals

(NASDAQ:DAWN)

Rating:50Neutral
Price Target:
Day One Biopharmaceuticals shows strong growth potential, particularly with the success of OJEMDA and a solid cash position. However, consistent net losses, negative technical indicators, and a challenging valuation due to ongoing losses present significant risks. The strong momentum from recent earnings highlights provides some optimism, balancing out the weaker financial and technical aspects.
Positive Factors
Financial Performance
Day One Biopharmaceuticals reported a robust cash position of $453.1MN, a best-in-class commercial product, and an experienced management, making it a buying opportunity.
Market Adoption
Ojemda quarterly prescriptions increased by 15%, with over 3,300 total prescriptions written in the US, highlighting strong adoption.
Product Growth
Steady growth is assumed for Ojemda with peak sales of over $500 million in the US.
Negative Factors
Earnings
The 2Q25 EPS of -$0.29, while slightly higher than consensus, reflects a challenging financial performance.
Revenue Guidance
The FY 2025 product net revenue guidance of $140M - $150M is lower than the consensus of $151.7M.
Sales Performance
Ojemda sales of $33.9M came in approximately 4.5% lower than consensus expectations.

Day One Biopharmaceuticals (DAWN) vs. SPDR S&P 500 ETF (SPY)

Day One Biopharmaceuticals Business Overview & Revenue Model

Company DescriptionDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
How the Company Makes MoneyDay One Biopharmaceuticals makes money primarily through the development and eventual commercialization of its oncology therapies. The company invests in research and development to create novel cancer treatments, which, upon successful clinical trials and regulatory approval, can be marketed and sold. Revenue streams include potential product sales, licensing agreements, and partnerships with larger pharmaceutical companies for the co-development or commercialization of their therapies. Additionally, Day One may secure funding through grants, collaborations, and strategic alliances that provide financial support during the clinical development stages.

Day One Biopharmaceuticals Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: 1.45%|
Next Earnings Date:Nov 10, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong positive sentiment with significant achievements in revenue growth, prescription numbers, and financial stability. The momentum of OJEMDA's launch and the promising pipeline developments outweighed the single noted lowlight of discontinuing the VRK1 program.
Q2-2025 Updates
Positive Updates
OJEMDA Surpasses Expectations
OJEMDA generated $113.1 million in cumulative net revenue in 12 months, demonstrating strong commercial momentum and sustained patient demand.
Double-Digit Revenue Growth
For the second quarter, Day One Biopharmaceuticals delivered $33.6 million in net product revenue, up 10% over the first quarter.
Strong Prescription Growth
The company exceeded 1,000 total prescriptions in Q2 for the first time, with a 15% quarter-over-quarter growth in prescriptions.
High Rate of Payer Coverage
Over 95% of patients on OJEMDA are paid patients, with about 90% receiving approval upon initial submission.
Robust Financial Position
Day One Biopharmaceuticals ended Q2 with $453 million in cash and no debt, ensuring flexibility to execute plans.
Promising Pipeline Developments
Advancing PTK7-targeted ADC, DAY301, through Phase Ia trial and the FIREFLY-2 trial for potential indication expansion of OJEMDA.
Negative Updates
Discontinued Investment in VRK1 Program
The company decided to discontinue its investment in the VRK1 program in-licensed from Sprint Biosciences.
Company Guidance
During the Day One Biopharmaceuticals Q2 2025 Earnings Conference Call, the company reported substantial growth and provided guidance for the fiscal year. OJEMDA, their lead product, achieved $33.6 million in net product revenue for Q2, marking a 10% increase over Q1 and contributing to a trailing 12-month revenue of $113.1 million. The company issued full-year 2025 net revenue guidance of $140 to $150 million, driven by strong demand, prescriber adoption, and payer coverage. The quarter saw over 1,000 prescriptions, with a 15% quarter-over-quarter growth in prescriptions. Day One highlighted a 95% paid patient rate and a 90% initial approval rate for OJEMDA. Additionally, they emphasized the strategic advantage of a strong balance sheet with $453 million in cash and no debt. They are progressing with the FIREFLY-2 trial and are advancing their PTK7-targeted ADC, DAY301, through Phase Ia trial dose escalation.

Day One Biopharmaceuticals Financial Statement Overview

Summary
Day One Biopharmaceuticals demonstrates growth potential with a notable revenue increase, but consistent net losses and reliance on external financing are key challenges. While the balance sheet shows some recovery, the company must focus on achieving operational profitability and stronger cash flows to enhance financial stability.
Income Statement
45
Neutral
Day One Biopharmaceuticals has shown a significant increase in revenue in the latest year, but they still operate at a net loss, reflecting a negative net profit margin. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges in achieving profitability.
Balance Sheet
40
Negative
The company maintains a low debt-to-equity ratio, suggesting conservative leverage. However, the negative equity in previous years indicates past financial instability. Recent improvements in equity position show progress, but the equity ratio suggests a need for further strengthening.
Cash Flow
50
Neutral
Cash flow from operations remains negative, yet there is notable improvement in free cash flow growth. The cash flow from financing reflects reliance on external funding, which could pose risks if not managed effectively.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue187.64M131.16M0.000.000.000.00
Gross Profit176.42M125.88M-383.00K-531.00K-199.00K-155.00K
EBITDA-110.08M-217.27M-206.06M-141.65M-72.56M-43.66M
Net Income-95.00M-95.50M-188.92M-132.18M-70.44M-40.51M
Balance Sheet
Total Assets519.04M582.79M376.05M349.06M289.82M45.66M
Cash, Cash Equivalents and Short-Term Investments453.10M531.72M366.35M342.27M284.31M43.73M
Total Debt3.00M2.60M408.00K813.00K220.00K402.00K
Total Liabilities58.20M80.04M29.51M17.02M8.67M94.16M
Stockholders Equity460.83M502.75M346.54M-269.67M-127.49M-54.20M
Cash Flow
Free Cash Flow-120.52M-80.28M-150.08M-109.90M-56.54M-13.58M
Operating Cash Flow-63.06M-78.11M-146.85M-109.87M-48.54M-13.49M
Investing Cash Flow-343.63M-230.99M128.38M-255.07M-8.00M-92.00K
Financing Cash Flow202.69M203.29M164.00M165.90M297.12M29.98M

Day One Biopharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.98
Price Trends
50DMA
6.62
Positive
100DMA
6.81
Positive
200DMA
9.40
Negative
Market Momentum
MACD
0.02
Negative
RSI
58.61
Neutral
STOCH
80.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DAWN, the sentiment is Positive. The current price of 6.98 is above the 20-day moving average (MA) of 6.59, above the 50-day MA of 6.62, and below the 200-day MA of 9.40, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 58.61 is Neutral, neither overbought nor oversold. The STOCH value of 80.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DAWN.

Day One Biopharmaceuticals Risk Analysis

Day One Biopharmaceuticals disclosed 94 risk factors in its most recent earnings report. Day One Biopharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Day One Biopharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$810.84M-43.63%-13.05%
60
Neutral
$1.07B-19.89%95.94%35.69%
55
Neutral
$1.19B222.83%35.62%49.58%
51
Neutral
$7.77B-0.12-39.78%2.21%22.68%-1.42%
50
Neutral
$698.59M-24.75%2190.50%52.85%
43
Neutral
$752.26M-50.67%41.86%10.48%
42
Neutral
$1.49B-63.96%-36.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DAWN
Day One Biopharmaceuticals
6.98
-7.11
-50.46%
AVXL
Anavex Life Sciences
9.55
3.23
51.11%
ZYME
Zymeworks
14.39
3.00
26.34%
XERS
Xeris Pharmaceuticals
7.59
4.71
163.54%
NRIX
Nurix Therapeutics
9.65
-14.37
-59.83%
PHVS
Pharvaris
23.35
5.50
30.81%

Day One Biopharmaceuticals Corporate Events

Business Operations and StrategyFinancial Disclosures
Day One Biopharmaceuticals Reports 2024 Financial Results
Positive
Feb 25, 2025

On February 25, 2025, Day One Biopharmaceuticals announced its financial results for the fourth quarter and full year 2024, reporting OJEMDA net product revenues of $29.0 million for Q4 and $57.2 million for the year. The company ended 2024 with $531.7 million in cash and investments, and highlighted the approval of OJEMDA as a catalyst for growth. Significant achievements included the Exclusively Pediatric designation for OJEMDA, progress in clinical trials, and increased R&D and SG&A expenses. The announcement reflects Day One’s strategic positioning for long-term growth and its commitment to advancing pediatric cancer treatments.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025